Dental problems delaying the initiation of interferon therapy for HCV-infected patients

Virology Journal

Volumn 7, Issue , 2010, Pages

  Nagao, Yumiko ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; IMMUNOLOGIC FACTOR; MACROGOL DERIVATIVE;

ADULT; AGED; ARTICLE; DENTAL CARE; FEMALE; GINGIVA DISEASE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIODONTITIS; SALIVATION; THERAPY DELAY; TOOTH DISEASE; MIDDLE AGED; MOUTH DISEASE;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; STOMATOGNATHIC DISEASES;

EID: 77955540810     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-192     Document Type: Article

References (25)

1. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. H Yoshizawa, Oncology 2002 62 Suppl 1 8 17 10.1159/000048270 11868791
2. Peginterferonalpha 2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. SJ Hadziyannis H Settee Jr TR Morgan V Balan M Diago P Marcellin G Ramadori H Bodenheimer Jr D Bernstein M Rizzetto S Zeuzem PJ Pockros A Lin AM Ackrill PEGASYS International Study Group, Ann Intern Med 2004 140 346 355 14996676
3. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindollar ZD Goodman K Koury M Ling JK Albrecht, Lancet 2001 358 958 965 10.1016/S0140-6736(01)06102- 5 11583749
4. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Gonçales Jr D Häussinger M Diago G Carosi D Dhumeaux A Craxi A Lin J Hoffman J Yu, N Engl J Med 2002 347 975 982 10.1056/NEJMoa020047 12324553
5. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. A Mangia N Minerva D Bacca R Cozzolongo GL Ricci V Carretta F Vinelli G Scotto G Montalto M Romano G Cristofaro L Mottola F Spirito A Andriulli, Hepatology 2008 47 43 50 10.1002/hep.22061 18069698
6. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. H Yoshida Y Shiratori M Moriyama Y Arakawa T Ide M Sata O Inoue M Yano M Tanaka S Fujiyama S Nishiguchi T Kuroki F Imazeki O Yokosuka S Kinoyama G Yamada M Omata, Ann Intern Med 1999 131 174 181 10428733
7. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. H Yoshida Y Arakawa M Sata S Nishiguchi M Yano S Fujiyama G Yamada O Yokosuka Y Shiratori M Omata, Gastroenterology 2002 123 483 491 10.1053/gast.2002.34785 12145802
8. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. T Okanoue Y Itoh M Minami S Sakamoto K Yasui M Sakamoto K Nishioji Y Murakami K Kashima, J Hepatol 1999 30 653 659 10.1016/S0168-8278(99)80196-2 10207807
9. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. V Mazzaferro R Romito M Schiavo L Mariani T Camerini S Bhoori L Capussotti F Calise R Pellicci G Belli A Tagger M Colombo F Bonino P Majno JM Llovet HCC Italian Task Force, Hepatology 2006 44 1543 1554 10.1002/hep.21415 17133492
10. Side effects of therapy of hepatitis C and their management. MW Fried, Hepatology 2002 36 5 Suppl 1 237 244 10.1002/hep.1840360730
11. Side effects of therapy for chronic hepatitis C. MW Russo MW Fried, Gastroenterology 2003 124 1711 1719 10.1016/S0016-5085(03)00394-9 12761728
12. Peginterferon and ribavirin for chronic hepatitis C. JH Hoofnagle LB Seeff, N Engl J Med 2006 355 2444 2451 10.1056/NEJMct061675 17151366
13. Hepatitis C infection and associated oral health problems. EA Coates D Brennan RM Logan AN Goss B Scopacasa AJ Spencer E Gorkic, Aust Dent J 2000 45 108 114 10.1111/j.1834-7819.2000.tb00249.x 10925506
14. The increasing problem of hepatitis C virus infection. EA Coates L Walsh R Logan, Aust Dent J 2001 46 13 17 10.1111/j.1834-7819.2001.tb00268.x 11355234
15. Oral health of patients with hepatitis C virus infection: a pilot study. L Henderson M Muir PR Mills E Spence R Fox EA McCruden J Bagg, Oral Dis 2001 7 271 275 10.1034/j.1601-0825.2001.00695.x 12117200
16. Oral health needs among adults in the United States with chronic diseases. SO Griffin LK Barker PM Griffin JL Cleveland W Kohn, J Am Dent Assoc 2009 140 1266 1274 19797557
17. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. SC Lee A Antony N Lee J Leibow JQ Yang S Soviero K Gutekunst M Rosenstraus, J Clin Microbiol 2000 38 4171 4179 11060086
18. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. D Sizmann C Boeck J Boelter D Fischer M Miethke S Nicolaus M Zadak R Babiel, J Clin Virol 2007 38 326 333 10.1016/j.jcv.2006.12.021 17344093
19. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. G Dusheiko H Schmilovitz-Weiss D Brown F McOmish PL Yap S Sherlock N McIntyre P Simmonds, Hepatology 1994 19 13 18 10.1002/hep.1840190104 8276349
20. Oral diseases associated with hepatitis C virus infection. Part 1. sialadenitis and salivary glands lymphoma. M Carrozzo, Oral Dis 2008 14 123 130 10.1111/j.1601-0825.2007.01436.x 18208477
21. Incidence of Sjögren's syndrome in Japanese patients with hepatitis C virus infection. Y Nagao S Hanada S Shishido T Ide R Kumashiro T Ueno M Sata, J Gastroenterol Hepatol 2003 18 258 266 10.1046/j.1440-1746.2003.02982.x 12603525
22. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. L Serfaty J Capeau, Liver Int 2009 29 Suppl 2 13 25 10.1111/j.1478-3231. 2008.01952.x 19187069
23. Insulin resistance and lichen planus in patients with HCV-infectious liver diseases. Y Nagao K Kawasaki M Sata, J Gastroenterol Hepatol 2008 23 580 585 10.1111/j.1440-1746.2007.04835.x 18397487
24. Periodontal inflammation and insulin resistance - lessons from obesity. F Nishimura Y Murayama, J Dent Res 2001 80 1690 1694 10.1177/00220345010800080201 11669476
25. HCV or HBV infection self-disclosure to dentist. Y Nagao T Kawaguchi T Ide M Sata, Kansenshogaku Zasshi 2008 82 213 219 18546851